TIDMMXCT TIDMTTM

RNS Number : 3613V

MaxCyte, Inc.

08 April 2019

MaxCyte, Inc.

("MaxCyte" or the "Company")

MaxCyte(R) Launches ExPERT(TM) Instrument Family to Provide a Unifying Technology Platform from Concept to Commercialization for Next-Generation Cellular Therapies

Instruments and disposables with enhanced design features and functionality also support expanded use in drug discovery

MaxCyte's high-growth, high-margin business generated revenues of $16.7m in 2018

Gaithersburg, Maryland - April 8, 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based medicines and life sciences company, announced today the launch of the new ExPERT(TM) technology platform. This family of instruments - the ATx, STx and GTx - represents the next generation of the industry's leading, clinically validated, Flow Electroporation(R) technology for complex cellular engineering that will further solidify the Company's leading position in the cell therapy and gene editing markets.

With these additions to the product portfolio, MaxCyte continues its uncompromising focus on high performance cellular editing, while delivering feature enhancements that will enable customers to use a single unifying technology, from concept to commercialization. ExPERT(TM) introduces new updated software, a touch-screen user interface and other features that deliver a significant improvement to the user experience. The combination of the new instruments, together with the launch of a new range of processing assemblies, will enable customers to standardize on a single, unifying technology from early research through to clinical and commercial use.

"The ExPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies," said Brad Calvin, Executive Vice President of Global Commercial Operations for MaxCyte. "Creating cellular editing platforms standardized on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies."

The ExPERT ATx, STx and GTx build on the solid technology foundation that has been the core of MaxCyte's historical instrument platforms, which are used by a broad client base, including all of the top ten biopharmaceutical companies by revenue, who are developing increasingly sophisticated biological and cellular-based therapeutics.

"We are proud to announce the launch of our next-generation ExPERT brand of instruments," said Doug Doerfler, MaxCyte's President and CEO. "We are committed to continually investing in our platform and delivering the essential tools, product features and technology performance that are critical to the advancement of promising new cellular therapeutics, which provide hope to many patients with previously incurable or life-threatening diseases."

The new instrument family can be viewed on-line at http://www.myexpertplatform.com/.

About MaxCyte

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered program licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

###

 
FFor further information, please contact: 
 
 MaxCyte Inc. 
Doug Doerfler, CEO 
 Brad Calvin, EVP, Global Commercial 
 Operations                                 +1 301 944 1660 
 
  Nominated Adviser and Broker 
  Panmure Gordon 
  Emma Earl 
  Freddy Crossley 
  Corporate Broking 
  James Stearns                               +44 (0)20 7886 2500 
Financial PR Adviser 
 Consilium Strategic Communications           +44 (0)203 709 5700 
 Mary-Jane Elliott                            maxcyte@consilium-comms.com 
 Chris Welsh 
 Sukaina Virji

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUGUQGCUPBPGM

(END) Dow Jones Newswires

April 08, 2019 02:00 ET (06:00 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Maxcyte Charts.
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Maxcyte Charts.